Abstract
Drug monitoring and safety is a daily challenge for clinicians. Pharmacovigilance is the study of adverse-drug reactions and iatrogenic diseases. If not always life-threatening, these reactions can impair patient’s overall and oral well-being and quality of life. Methods for quantifying the risk of drug use are numerous, ranging from experimental pharmacology and toxicology observations to the results of clinical trials and pharmacoepidemiology data. This chapter also underlines the importance of pharmacogenetics and pharmacogenomics approaches.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Bibliography
Abou Taam M, Rossard C, Cantaloube I, Bouscaren N, Pochard L, Montastruc F, Montastruc JL, Bagheri H. Analyse of internet narratives on patient websites before and after benfluorex withdrawal and media coverage. Fundam Clin Pharmacol. 2012;26(Suppl 1):79.
Bagheri H, Lacroix I, Bondon-Guitton E, Damase-Michel C, Montastruc JL. Cyberpharmacovigilance: what is the usefulness of the social networks in pharmacovigilance? Therapie. 2016;71:241–4.
Baron JA, Sandler RS, Bresalier RS, Lanas A, Morton DG, Riddell R, Iverson ER, Demets DL. Cardiovascular events associated with rofecoxib: final analysis of the APPROVe trial. Lancet. 2008;372:1756–64.
Belton KJ. Attitude survey of adverse drug-reaction reporting by health care professionals across the European Union. The European Pharmacovigilance Research Group. Eur J Clin Pharmacol. 1997;52:423–7.
Bondon-Guitton E, Despas F, Becquemont L. The contribution of pharmacogenetics to pharmacovigilance. Therapie. 2016;71:223–8.
But TF, Cox AR, Oyebode J, Ferner RE. Internet accounts of survivors of serious adverse drug reactions: a study of experiences of Stevens Johnson syndrome and toxic epidermal necrolysis. Drug Saf. 2011;34:898.
Caillet C, Durrieu G, Jacquet A, Faucher A, Ouaret S, Perrault-Pochat MC, Kreft-Jaïs C, Castot A, Montastruc JL, French Network of Pharmacovigilance Centres. Safety surveillance of influenza A(H1N1)v monovalent vaccines during the 2009-2010 mass vaccination campaign in France. Eur J Clin Pharmacol. 2011;67(6):649–51.
Carpenter D, Zucker EJ, Avorn J. Drug-review deadlines and safety problems. N Engl J Med. 2008;358:1354–61.
Faillie JL. Case-non case studies: principles, methods, bias and interpretation. Therapie. 2018;73:247–55. pii: S0040-5957(17)30178-6.
Faillie JL, Montastruc F, Montastruc JL, Pariente A. Pharmacoepidemiology and its input to pharmacovigilance. Therapie. 2016;71:211–6.
Hazell L, Shakir SA. Under-reporting of adverse drug reactions: a systematic review. Drug Saf. 2006;29:385–96.
Hillaire-Buys D, Faillie JL, Montastruc JL. Pioglitazone and bladder cancer. Lancet. 2011;378:1543–4.
Lafond J. Pharmacovigilance implemented by patients: a necessity in the 21th century. Therapie. 2016;71:245–8.
Lagnaoui R, Moore N, Fach J, Longy-Boursier M, Begaud B. Adverse drug reactions in a department of systemic diseases-oriented internal medicine: prevalence, incidence, direct costs and avoidability. Eur J Clin Pharmacol. 2000;56:181–6.
Laroche ML, Batz A, Geniaux H, Fechant C, Merle L, Maison P. Pharmacovigilance in Europe: place of the Pharmacovigilance Risk Assessment Committee (PRAC) in organization and decisional process. Therapie. 2016;71:161–70.
Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA. 1998;279:1200–5.
Lugardon S, Desboeuf K, Fernet P, Montastruc JL, Lapeyre-Mestre M. Using a capture-recapture method to assess the frequency of adverse drug reactions in a French university hospital. Br J Clin Pharmacol. 2006;62:225–31.
Miremont-Salamé G, Théophile H, Haramburu F, Bégaud B. Causality assessment in pharmacovigilance: the French method and its successive updates. Therapie. 2016;71:179–86.
Montastruc JL, Bagheri H, Geraud T, Lapeyre-Mestre M. Pharmacovigilance of self-medication. Therapie. 1997;52:105–10.
Montastruc JL, Sommet A, Lacroix I, Olivier P, Durrieu G, Damase-Michel C, Lapeyre-Mestre M, Bagheri H. Pharmacovigilance for evaluating adverse drug reactions: value, organization, and methods. Joint Bone Spine. 2006;73:629–32.
Montastruc F, Palmaro A, Bagheri H, Schmitt L, Montastruc JL, Lapeyre-Mestre M. Role of serotonin 5-HT2C and histamine H1 receptors in antipsychotic-induced diabetes: a pharmacoepidemiological-pharmacodynamic study in VigiBase. Eur Neuropsychopharmacol. 2015;25:1556–65.
Olivier P, Boulbes O, Tubery M, Lauque D, Montastruc JL, Lapeyre-Mestre M. Assessing the feasibility of using an adverse drug reaction preventability scale in clinical practice: a study in a French emergency department. Drug Saf. 2002;25:1035–44.
Pouyanne P, Haramburu F, Imbs JL, Begaud B. Admissions to hospital caused by adverse drug reactions: cross sectional incidence study. French Pharmacovigilance Centres. Br Med J. 2000;320:1036.
Smith Rogers A. Adverse drug events: identification and attribution. Drug Intell Clin Pharm. 1987;21:915–20.
Vial T. French pharmacovigilance: missions, organization and perspectives. Therapie. 2016;71:143–50.
Zed PJ, Abu-Laban RB, Balen RM, Loewen PS, Hohl CM, Brubacher JR, Wilbur K, Wiens MO, Samoy LJ, Lacaria K, Purssell RA. Incidence, severity and preventability of medication-related visits to the emergency department: a prospective study. CMAJ. 2008;178:1563–9.
Conflicts of Interest
None.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2021 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Montastruc, JL., Bagheri, H., Durrieu, G., Lacroix, I., Montastruc, F. (2021). Adverse Drug Reactions, Iatrogenic Diseases, Drug Safety, and Pharmacovigilance: Importance and Interest for Patients and Their Physicians. In: Cousty, S., Laurencin-Dalicieux, S. (eds) Drug-Induced Oral Complications. Springer, Cham. https://doi.org/10.1007/978-3-030-66973-7_1
Download citation
DOI: https://doi.org/10.1007/978-3-030-66973-7_1
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-66972-0
Online ISBN: 978-3-030-66973-7
eBook Packages: MedicineMedicine (R0)